Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Geneva Task Force for the Roadmap of Alzheimer's Biomarkers

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers. Phase 3 (utility in MCI) is partially achieved. In cohorts with long follow-up time, CSF Aβ42, total tau, and phosphorylated tau have high diagnostic accuracy for MCI due to AD. Phase 4 (performance in real world) is ongoing, and phase 5 studies (quantify impact and costs) are to come. Our results highlight priorities to pursue and to enable the proper use of CSF biomarkers in the clinic. Priorities are to reduce measurement variability by introduction of fully automated assay systems; to increase diagnostic specificity toward non-AD neurocognitive diseases at the MCI stage; and to clarify the role of CSF biomarkers versus other biomarker modalities in clinical practice and in design of clinical trials. These efforts are currently ongoing.

Original languageEnglish
Pages (from-to)196-213
Number of pages18
JournalNeurobiology of Aging
Volume52
DOIs
Publication statusPublished - Apr 1 2017
Externally publishedYes

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Prodromal Symptoms
Clinical Trials
Costs and Cost Analysis
Cognitive Dysfunction

Keywords

  • 5-Phases
  • Alzheimer's disease
  • Beta-amyloid
  • Biomarker development
  • Biomarker-based diagnosis
  • Cerebrospinal fluid
  • Early diagnosis
  • Phosphorylated tau
  • Tau

ASJC Scopus subject areas

  • Neuroscience(all)
  • Ageing
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. / Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

In: Neurobiology of Aging, Vol. 52, 01.04.2017, p. 196-213.

Research output: Contribution to journalReview article

@article{6c019f1de5b4476eaee7546d45050993,
title = "Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework",
abstract = "Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers. Phase 3 (utility in MCI) is partially achieved. In cohorts with long follow-up time, CSF Aβ42, total tau, and phosphorylated tau have high diagnostic accuracy for MCI due to AD. Phase 4 (performance in real world) is ongoing, and phase 5 studies (quantify impact and costs) are to come. Our results highlight priorities to pursue and to enable the proper use of CSF biomarkers in the clinic. Priorities are to reduce measurement variability by introduction of fully automated assay systems; to increase diagnostic specificity toward non-AD neurocognitive diseases at the MCI stage; and to clarify the role of CSF biomarkers versus other biomarker modalities in clinical practice and in design of clinical trials. These efforts are currently ongoing.",
keywords = "5-Phases, Alzheimer's disease, Beta-amyloid, Biomarker development, Biomarker-based diagnosis, Cerebrospinal fluid, Early diagnosis, Phosphorylated tau, Tau",
author = "Niklas Mattsson and Anders L{\"o}nneborg and Marina Boccardi and Kaj Blennow and Oskar Hansson and {Geneva Task Force for the Roadmap of Alzheimer's Biomarkers}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.neurobiolaging.2016.02.034",
language = "English",
volume = "52",
pages = "196--213",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

AU - Mattsson, Niklas

AU - Lönneborg, Anders

AU - Boccardi, Marina

AU - Blennow, Kaj

AU - Hansson, Oskar

AU - Geneva Task Force for the Roadmap of Alzheimer's Biomarkers

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers. Phase 3 (utility in MCI) is partially achieved. In cohorts with long follow-up time, CSF Aβ42, total tau, and phosphorylated tau have high diagnostic accuracy for MCI due to AD. Phase 4 (performance in real world) is ongoing, and phase 5 studies (quantify impact and costs) are to come. Our results highlight priorities to pursue and to enable the proper use of CSF biomarkers in the clinic. Priorities are to reduce measurement variability by introduction of fully automated assay systems; to increase diagnostic specificity toward non-AD neurocognitive diseases at the MCI stage; and to clarify the role of CSF biomarkers versus other biomarker modalities in clinical practice and in design of clinical trials. These efforts are currently ongoing.

AB - Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers. Phase 3 (utility in MCI) is partially achieved. In cohorts with long follow-up time, CSF Aβ42, total tau, and phosphorylated tau have high diagnostic accuracy for MCI due to AD. Phase 4 (performance in real world) is ongoing, and phase 5 studies (quantify impact and costs) are to come. Our results highlight priorities to pursue and to enable the proper use of CSF biomarkers in the clinic. Priorities are to reduce measurement variability by introduction of fully automated assay systems; to increase diagnostic specificity toward non-AD neurocognitive diseases at the MCI stage; and to clarify the role of CSF biomarkers versus other biomarker modalities in clinical practice and in design of clinical trials. These efforts are currently ongoing.

KW - 5-Phases

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Biomarker development

KW - Biomarker-based diagnosis

KW - Cerebrospinal fluid

KW - Early diagnosis

KW - Phosphorylated tau

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85015610082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015610082&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2016.02.034

DO - 10.1016/j.neurobiolaging.2016.02.034

M3 - Review article

VL - 52

SP - 196

EP - 213

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -